×

Annual Changes to the NASDAQ Biotechnology Index

NEW YORK, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 18, 2017.

The following 54 securities will be added to the Index:

ExchangeSYMBOLCOMPANY NAME
NasdaqABUSArbutus Biopharma Cp
NasdaqACRSAclaris Therapeutics, Inc.
NasdaqADAPAdaptimmune Theraptcs plc
NasdaqAKAOAchaogen, Inc.
NasdaqAKCAAkcea Therapeutics, Inc.
NasdaqANABAnaptysBio, Inc.
NasdaqASNDAscendis Pharma
NasdaqATNXAthenex, Inc.
NasdaqAUPHAurinia Pharmaceuticals
NasdaqAXONAxovant Sciences Ltd
NasdaqBIVVBioverativ Inc.
NasdaqCALACalithera Biosciences Com
NasdaqCARACara Therapeutics, Inc.
NasdaqCASCCascadian Therapeutics Inc
NasdaqCLLSCellectis S.A.
NasdaqCLXTCalyxt, Inc.
NasdaqCMRXChimerix, Inc.
NasdaqCNCEConcert Pharmaceuticals, Inc.
NasdaqCORICorium International
NasdaqCRBPCorbus Pharma Hlds
NasdaqCRSPCRISPR Therapeutics AG
NasdaqCRVSCorvus Pharma
NasdaqCTMXCytomX Therapeutics, Inc.
NasdaqDOVADova Pharmaceuticals, Inc.
NasdaqECYTEndocyte, Inc.
NasdaqGLPGGalapagos NV
NasdaqGLYCGlycoMimetics, Inc.
NasdaqGTHXG1 Therapeutics, Inc.
NasdaqIMGNImmunoGen, Inc.
NasdaqJNCEJounce Therapeutics, Inc.
NasdaqKALAKala Pharmaceuticals, Inc.
NasdaqKURAKura Oncology, Inc.
NasdaqMEDPMedpace Holdings, Inc.
NasdaqMNKDMannKind Corporation
NasdaqMRNSMarinus Pharmaceuticals
NasdaqMRSNMersana Therapeutics
NasdaqMYOKMyoKardia, Inc. St
NasdaqNBRVNabriva Therapeutics plc
NasdaqNEOSNeos Therapeutics, Inc.
NasdaqPBYIPuma Biotechnology
NasdaqPETQPetIQ, Inc.
NasdaqQUREuniQure NV
NasdaqRARXRa Pharmaceuticals
NasdaqRETAReata Pharmaceuticals
NasdaqSBBPStrongbridge Biopharma plc
NasdaqSNDXSyndax Pharmaceuticals
NasdaqSNNASienna Biopharmaceuticals
NasdaqSVRASavara Inc.
NasdaqTOCATocagen Inc.
NasdaqTTPHTetraphase Pharmaceuticals, Inc
NasdaqTXMDTHERAPEUTICSMD INC
NasdaqVCYTVeracyte Inc
NasdaqVTLVital Therapies, Inc.
NasdaqVYGRVoyager Therapeutics

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

As a result of the re-ranking, the following 15 securities will be removed from the Index:

ExchangeSYMBOLCOMPANY NAME
NasdaqAQXPAquinox Pharmaceuticals, Inc.
NasdaqARLZAralez Pharmaceuticals Inc.
NasdaqCGENCompugen Ltd
NasdaqCLSDClearside Biomedical, Inc.
NasdaqIPXLImpax Laboratories, Inc.
NasdaqMACKMerrimack Pharmactl
NasdaqMLNTCempra Inc
NasdaqMNOVMedicinova Inc
NasdaqOMEDOncoMed Pharmaceuticals, Inc.
NasdaqONVOOrganovo Hldgs Inc
NasdaqOPHTOphthotech Corp
NasdaqOTICOtonomy, Inc.
NasdaqTRVNTrevena, Inc.
NasdaqVSARVersartis, Inc.
NasdaqXBITXBiotech Inc.

About Nasdaq Global Indexes

Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide-spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index and design solutions to financial organizations worldwide.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

NDAQG

Media Contact:
Christine Barna, Nasdaq
(646) 441-5310

Issuer & Investor Contact:
Natasha Selzer, Nasdaq
(301)978-8623
Carla Proto, Nasdaq
(203) 926-3326

Source:Nasdaq, Inc.